➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Baxter
Merck
McKinsey
Harvard Business School
Boehringer Ingelheim

Last Updated: August 9, 2020

DrugPatentWatch Database Preview

VERAPAMIL HYDROCHLORIDE Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Verapamil Hydrochloride, and what generic alternatives are available?

Verapamil Hydrochloride is a drug marketed by Mylan, Abraxis Pharm, Bedford, Hospira, Intl Medication, Luitpold, Marsam Pharms Llc, Smith And Nephew, Solopak, Amneal, Areva Pharms, Caplin, Exela Pharma Scs Llc, Micro Labs, Somerset, Somerset Theraps Llc, Apotex Corp, Cadila Pharms Ltd, Glenmark Generics, Ivax Sub Teva Pharms, Par Pharm, Pliva, Sun Pharm Inds Inc, Actavis Elizabeth, Heritage Pharms Inc, Mutual Pharm, Sun Pharm Industries, Warner Chilcott, Watson Labs, and Yaopharma Co Ltd. and is included in fifty-nine NDAs.

The generic ingredient in VERAPAMIL HYDROCHLORIDE is verapamil hydrochloride. There are seventeen drug master file entries for this compound. Thirty-nine suppliers are listed for this compound. Additional details are available on the verapamil hydrochloride profile page.

US ANDA Litigation and Generic Entry Outlook for Verapamil Hydrochloride

A generic version of VERAPAMIL HYDROCHLORIDE was approved as verapamil hydrochloride by EXELA PHARMA SCS LLC on March 30th, 1984.

  Start Trial

Drug patent expirations by year for VERAPAMIL HYDROCHLORIDE
Recent Clinical Trials for VERAPAMIL HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Centre Hospitalier Universitaire de NicePhase 4
Tanta UniversityEarly Phase 1
Assiut UniversityEarly Phase 1

See all VERAPAMIL HYDROCHLORIDE clinical trials

Medical Subject Heading (MeSH) Categories for VERAPAMIL HYDROCHLORIDE
Paragraph IV (Patent) Challenges for VERAPAMIL HYDROCHLORIDE
Tradename Dosage Ingredient NDA Submissiondate
VERELAN PM CAPSULE, EXTENDED RELEASE;ORAL verapamil hydrochloride 020943 2006-07-20
VERELAN PM CAPSULE, EXTENDED RELEASE;ORAL verapamil hydrochloride 020943 2006-05-19
COVERA-HS TABLET, EXTENDED RELEASE;ORAL verapamil hydrochloride 020552

US Patents and Regulatory Information for VERAPAMIL HYDROCHLORIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Warner Chilcott VERAPAMIL HYDROCHLORIDE verapamil hydrochloride TABLET;ORAL 070341-001 Sep 24, 1986 DISCN No No   Start Trial   Start Trial   Start Trial
Cadila Pharms Ltd VERAPAMIL HYDROCHLORIDE verapamil hydrochloride TABLET, EXTENDED RELEASE;ORAL 206173-002 May 5, 2017 AB RX No No   Start Trial   Start Trial   Start Trial
Micro Labs VERAPAMIL HYDROCHLORIDE verapamil hydrochloride SOLUTION;INTRAVENOUS 211370-002 Dec 28, 2018 AP RX No No   Start Trial   Start Trial   Start Trial
Mylan VERAPAMIL HYDROCHLORIDE verapamil hydrochloride TABLET, EXTENDED RELEASE;ORAL 074587-003 Sep 9, 1997 AB RX No No   Start Trial   Start Trial   Start Trial
Heritage Pharms Inc VERAPAMIL HYDROCHLORIDE verapamil hydrochloride TABLET;ORAL 071881-003 Apr 5, 1988 AB RX No No   Start Trial   Start Trial   Start Trial
Ivax Sub Teva Pharms VERAPAMIL HYDROCHLORIDE verapamil hydrochloride TABLET, EXTENDED RELEASE;ORAL 073568-002 Oct 10, 1997 AB RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Boehringer Ingelheim
Colorcon
Dow
Medtronic
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.